56 filings
8-K
GRI
GRI Bio Inc
20 May 24
Entry into a Material Definitive Agreement
4:13pm
8-K
GRI
GRI Bio Inc
13 May 24
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
8:02am
8-K
GRI
GRI Bio Inc
1 Apr 24
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
9:13am
8-K
GRI
GRI Bio Inc
2 Feb 24
GRI Bio Announces Pricing of $5.5 Million Public Offering
4:23pm
8-K
GRI
GRI Bio Inc
30 Jan 24
GRI Bio Announces Reverse Stock Split
8:12am
8-K
ze7h7d217fh6c3zl i1
19 Jan 24
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
9bo2vdatd d2
16 Jan 24
Regulation FD Disclosure
8:45am
8-K
tcua1i8ak5fduj
5 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:05pm
8-K
wh4xhslc whmh
5 Dec 23
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway
9:07am
8-K
11bv1w20nipl5dpx
27 Nov 23
Clinical development plan leveraging 505(b)(2) regulatory pathway
8:38am
8-K
8a5lvnoq69
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
8-K
27ttg4zuumx9bo7wa 08
15 Nov 23
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024
8:07am
8-K
yr6j1b3
1 Nov 23
Regulation FD Disclosure
8:45am
8-K
dj5sal95l7ebsr
25 Aug 23
Regulation FD Disclosure
4:42pm
8-K
fjdtqbsqgczw5bvokn
23 Aug 23
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
9:07am
8-K
86dvrqop0p1neq0ph7ul
14 Aug 23
On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023
8:06am
8-K
3hmb7
7 Jul 23
Submission of Matters to a Vote of Security Holders
4:03pm
8-K/A
l7tw5a 83rfy1fk4o1
6 Jul 23
Financial Statements and Exhibits
4:28pm
8-K/A
r2nwzm
26 May 23
Financial Statements and Exhibits
4:15pm
8-K
nd7qaj2wh zmhxjqjel
27 Apr 23
Other Events
9:12am